Physician profile
William H Resh
NPI 1083637235
$39,257.25
in general payments reported to CMS, 2019-2025
30 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $3,612 · 2021: $5,344 · 2022: $2,556 · 2023: $947 · 2024: $1,039 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,021 · Education: $65.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,020.59 |
| Education | $65.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $33,292.30 | 2019-2022 | |
| Acutus Medical, INC. | $1,160.18 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $698.40 | 2021-2025 | |
| Abbott Laboratories | $538.02 | 2023-2025 | Aveir, Cardiomems, Gallant |
| Janssen Pharmaceuticals, INC | $461.47 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $460.55 | 2020-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $224.29 | 2019-2025 | Verquvo, Winrevair |
| Amgen INC. | $223.07 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $222.28 | 2023-2025 | Watchman Flx |
| Kestra Medical Technology Services, INC. | $203.37 | 2024-2025 | Assure Wcd |
| Infobionic, INC | $198.51 | 2025 | Mome Device |
| Impulse Dynamics (USA) INC. | $181.41 | 2020-2022 | |
| W. L. Gore & Associates, INC. | $169.99 | 2025 | Gore Tag Thoracic Branch Endoprosthesis |
| Pfizer INC. | $127.39 | 2022-2025 | |
| Abiomed | $125.94 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $117.28 | 2023-2024 | |
| Baxter Healthcare | $111.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $101.08 | 2021-2023 | |
| Axonics, INC. | $90.78 | 2022 | |
| Alnylam Pharmaceuticals INC. | $89.18 | 2022-2025 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $81.10 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.22 | 2023-2024 | Jardiance |
| Bridgebio Pharma, INC. | $68.88 | 2025 | Attruby |
| Astellas Pharma US INC | $53.81 | 2019-2021 | |
| Cleerly, INC. | $49.55 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Bayer Healthcare Pharmaceuticals INC. | $49.47 | 2021-2023 | |
| Novo Nordisk INC | $34.22 | 2022-2023 | Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.59 | 2021 | |
| Esperion Therapeutics, INC. | $17.38 | 2021 | |
| Cvrx, INC. | $14.59 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Resh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.